Title : Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.

Pub. Date : 2000 Nov

PMID : 11129289






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Paclitaxel was chosen for combination therapy in the preclinical study reported here due to its extensive use as a first-line therapy in ovarian cancer, its synergy with SCH58500 in preclinical cancer models, and its activation of p53-independent apoptosis, which might result in a "lowered threshold" for tumor cell death. Paclitaxel tumor protein p53 Homo sapiens